Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. 1991

I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
Department of Pediatrics and Microbiology, Tel Aviv University School of Medicine, Hasharon Hospital, Petah Tiqva, Israel.

In a prospective randomized open study, ceftriaxone, 50 mg/kg per day, was compared with ampicillin, 100 mg/kg per day, both given for a period of 5 days, for the treatment of 40 children whose mean (+/- SD) age was 4.5 +/- 3.2 years and who had severe dysentery caused by Shigella organisms. Twenty patients were treated with ceftriaxone and 20 with ampicillin. Both drugs were initially given intravenously for a period of 1 to 2 days and were continued intramuscularly, in the case of ceftriaxone, or orally, in the patients receiving ampicillin. All Shigella organisms isolated were susceptible to ceftriaxone; 28% were resistant to ampicillin. The diarrhea persisted for a mean (+/- SD) period of 2.5 +/- 1.0 days in the ceftriaxone-treated patients versus 6.8 +/- 6.3 days in the ampicillin-treated patients (p less than 0.005). At the end of the 5 days of therapy, stool cultures for Shigella organisms were negative in 12 (60%) of the 20 patients from the ampicillin group and in all the children (100%) from the ceftriaxone group (p less than 0.001). Bacteriologic relapses were observed in eight (40%) of the patients treated with ampicillin but in none of the children treated with ceftriaxone (p less than 0.001). In instances of clinical or bacteriologic failure in the ampicillin group, retreatment was instituted in most of the cases with ceftriaxone; persistent clearing of the Shigella organisms from the stool was finally achieved after a mean (+/- SD) period of 11.75 +/- 9.4 days after therapy was started, as compared with 1.85 +/- 0.6 days in the ceftriaxone-treated patients (p less than 0.001). We conclude that in children with severe shigellosis, treatment with ceftriaxone for 5 days is effective and better than use of ampicillin for clinical cure and eradication of the Shigella organisms from the stool.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004405 Dysentery, Bacillary DYSENTERY caused by gram-negative rod-shaped enteric bacteria (ENTEROBACTERIACEAE), most often by the genus SHIGELLA. Shigella dysentery, Shigellosis, is classified into subgroups according to syndrome severity and the infectious species. Group A: SHIGELLA DYSENTERIAE (severest); Group B: SHIGELLA FLEXNERI; Group C: SHIGELLA BOYDII; and Group D: SHIGELLA SONNEI (mildest). Shigellosis,Dysentery, Shiga bacillus,Dysentery, Shigella boydii,Dysentery, Shigella dysenteriae,Dysentery, Shigella dysenteriae type 1,Dysentery, Shigella flexneri,Dysentery, Shigella sonnei,Shigella Dysentery,Shigella Infection,Bacillary Dysentery,Dysenteries, Shigella,Dysenteries, Shigella boydii,Dysenteries, Shigella dysenteriae,Dysenteries, Shigella flexneri,Dysenteries, Shigella sonnei,Dysentery, Shigella,Infection, Shigella,Infections, Shigella,Shiga bacillus Dysentery,Shigella Dysenteries,Shigella Infections,Shigella boydii Dysenteries,Shigella boydii Dysentery,Shigella dysenteriae Dysenteries,Shigella dysenteriae Dysentery,Shigella flexneri Dysenteries,Shigella flexneri Dysentery,Shigella sonnei Dysenteries,Shigella sonnei Dysentery
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000667 Ampicillin Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. Penicillin, Aminobenzyl,Amcill,Aminobenzylpenicillin,Ampicillin Sodium,Ampicillin Trihydrate,Antibiotic KS-R1,Omnipen,Pentrexyl,Polycillin,Ukapen,Aminobenzyl Penicillin,Antibiotic KS R1,KS-R1, Antibiotic,Sodium, Ampicillin,Trihydrate, Ampicillin

Related Publications

I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
April 1973, Archives of disease in childhood,
I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
April 1998, Acta paediatrica Japonica : Overseas edition,
I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
April 1986, Antimicrobial agents and chemotherapy,
I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
April 1975, Antimicrobial agents and chemotherapy,
I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
February 1981, The Journal of infectious diseases,
I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
May 1968, Southern medical journal,
I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
June 1983, Lancet (London, England),
I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
May 1984, Antimicrobial agents and chemotherapy,
I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
September 1989, The Pediatric infectious disease journal,
I Varsano, and T Eidlitz-Marcus, and M Nussinovitch, and I Elian
November 1987, Pathologie-biologie,
Copied contents to your clipboard!